Trial Profile
A Phase IV, Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Trial and Subsequent Open-Label, Extension Trial to Assess the Safety and Efficacy of Addition of Omarigliptin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Monotherapy in Addition to Diet and Exercise Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Omarigliptin (Primary) ; Insulin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 01 Jun 2021 Primary endpoint (Constrained Longitudinal Data Analysis of Change From Baseline in Hemoglobin A1c (HbA1c) at Week 16 Excluding Data After Glycemic Rescue (Phase A)) has been met. according to the results published in the Diabetes, Obesity and Metabolism.
- 01 Jun 2021 Results assessing the efficacy, safety and tolerability of once weekly omarigliptin 25mg up to 52 weeks, published in the Diabetes, Obesity and Metabolism.
- 31 Aug 2018 Status changed from active, no longer recruiting to completed.